Dr. Strader is a general gastroenterologist/hepatologist with a special interest in liver diseases; specifically hepatitis B, hepatitis C and non-alcoholic fatty liver disease (NAFLD). She has been a member of the AASLD (American Association for the Study of Liver Diseases) for > 20 years, was a coauthor on the initial AASLD Guidelines for management of hepatitis C, was involved in the NIH Consensus Conference for the management of hepatitis B, has been involved in a number of clinical trials of treatment of NAFLD, was recently granted the status of Fellow of the AASLD, has served on numerous committees for the organization, given a number of invited lectures and moderated sessions during the Annual Meeting, and currently serves as Chair of the Data Safety Monitoring Committee of the National Institutes of Health Hepatitis B Research Network. Her ongoing research projects include treatment trials of NAFLD, and an investigator-initiated review of our recent management of esophageal food bolus impaction.
Viral hepatitis, hepatitis C, cirrhosis, nonalcoholic fatty liver disease, autoimmune liver disease, eosinophilic esophagitis, endoscopy, colonoscopy
For a complete list of publications click here:
https://www.ncbi.nlm.nih.gov/pubmed?term=Strader%2C+Doris%5Bauthor%5D&cmd=detailssearch
Understudied Populations. NIH Consensus Conference on the Management of Hepatitis C. Hepatology Nov 2000;36(5)suppl 1:S226-S236
The Use of Complementary medicines in Liver Disease clinics in the U.S. Strader DB, Hoofnagle J, Bacon B, Lindsay K, LaBrecque D, Morgan T, Wright E, Allen J, Seeff LB. American Journal of Gastroenterology Sept 2002;97(9):2391-2398.
High-density lipoproteins from human alcoholics exhibit impaired reverse cholesterol transport function. Rao MN, Lui Q-H, Marmillot P, Seeff LB, Strader DB, Lakshman MR. Metabolism 2000;49(11):1406-1410.
Complementary and Alternative Medicine in Hepatitis C. Strader DB, Zimmerman HJ. In: Liang, TJ and Hoofnagle JH, eds. Hepatitis C. New York: Academic Press, 2000:427-451.
Drug-Induced Chronic Liver Disease. Strader DB, Seeff LB. Clinics in Liver Disease 1998;Aug;2(3):501-522.
Training
BS Zoology, 1979, University of Maryland
MD, 1982-1987, Georgetown University School of Medicine
Intern/Residency, 1988-1991, University of Maryland School, Medicine
Fellowship, 1992-1994, VAMC/Georgetown/NIH Gastroenterology National Institutes of Health, Gastroenterology
Georgetown University School of Medicine
Assistant Professor of Medicine 3800 Resevoir Road, Washington, D.C. 20007 - 7/94 – present
The Relationship of CD81 Polymorphism to Clinical Disease in African-American an Caucasian Patients with Hepatitis C Virus Infection. Kerr GS, Martin MP, Strader DB, Carrington MN. 2/99 – present.
The Use of Complementary medicines in Liver Disease clinics in the U.S. Strader DB, Hoofnagle J, Bacon B, Lindsay K, LaBrecque D, Morgan T, Wright E, Allen J, Seeff LB.; 5/99 - 8/99.
Early Detection of Esophageal cancer/dysplasia in a high-risk population via Chromoendocscopy. Strader DB, Fleischer DE, Dawsey S, Eisen G, Lipman TO, Agarwal M, Wadleigh R.; 3/96 to present.
The Use of Rebetron in the Treatment of HIV/HCV Coinfected Patients. Benator D, Gibert C, Strader DB, Sharma A.; 6/99 – 10/01.
The Use of Rebetron for the Treatment of Naïve Patients with Hepatitis C – Dose Finding Study. Seeff LB, Strader DB (Schering-Plough coop study); 9/97 - 3/98.
The Use of Interferon/ Ribavirin in Patients with Hepatitis C who Relapsed on previous Interferon-Alone. Seeff LB, Strader DB, Sharma A.(Schering-Plough coop study); 3/97 – 11/99.
The Use of Alpha-Interferon in the treatment of Patients with Hepatitis C. Seeff LB, Strader DB (Schering-Plough coop study); approximately 1/95 – 6/97.
A Study of Lamivudine or Placebo in Patients with Chronic Hepatitis B Infection who are Treatment Naïve. Seeff LB, Strader DB (Glaxo-Sponsored study); 4/95-6/98
A Two-Stage Phase II Safety and Efficacy Study of IntraDose TM (Cisplatin/Epinephrine) Injectable Gel (MPI5010) Administered to Patients with Unresectable Primary Hepatocellular Carcinoma. Strader DB, Adib H, Seeff LB (Matrix-sponsored coop study); 9/96 – 9/97.
A Multicenter Trial to Evaluate the Epidemiology, Natural History and Treatment Response of Hepatitis C in the United States Veteran Population. Wright TL, Jeffers L, Rossi S. (Schering-Plough sponsored); 9/99 – 11/01.